222 related articles for article (PubMed ID: 25265933)
61. Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy.
Katoch K; Ramu G; Ramanathan U; Sengupta U; Sreevatsa
Indian J Lepr; 1987; 59(1):36-43. PubMed ID: 3611859
[TBL] [Abstract][Full Text] [Related]
62. A comparative clinical trial in multibacillary leprosy with long-term relapse rates of four different multidrug regimens.
Fajardo TT; Villahermosa L; Pardillo FE; Abalos RM; Burgos J; Dela Cruz E; Gelber RH
Am J Trop Med Hyg; 2009 Aug; 81(2):330-4. PubMed ID: 19635893
[TBL] [Abstract][Full Text] [Related]
63. Comparative study of two regimens of combined chemotherapy of one year duration in multibacillary leprosy. Results after four and five years' follow-up.
Pattyn SR; André PS; Ferracci C; Baquillon G
Int J Lepr Other Mycobact Dis; 1984 Sep; 52(3):297-303. PubMed ID: 6541198
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of two multidrug regimen in hospitalised multibacillary cases.
Chattopadhyay SP; Gupta CM; Bhate RD; Bhate RP; Sreevatsa
Indian J Lepr; 1989 Apr; 61(2):196-205. PubMed ID: 2746028
[TBL] [Abstract][Full Text] [Related]
65. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
[TBL] [Abstract][Full Text] [Related]
66. Multidrug therapy in hospitalised leprosy cases.
Tiwari VD; Tutakne MA; Singh G; Dutta RK
Indian J Lepr; 1988 Jan; 60(1):71-6. PubMed ID: 3204277
[TBL] [Abstract][Full Text] [Related]
67. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
68. Rate of relapse in multibacillary patients after cessation of long-course dapsone monotherapy supplemented by a final supervised single dose of 1500 mg of rifampin.
Cartel JL; Naudin JC
Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):215-9. PubMed ID: 8046260
[TBL] [Abstract][Full Text] [Related]
69. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
Chandorkar AG; Burte NP; Gade RK; Bulakh PM
Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
[TBL] [Abstract][Full Text] [Related]
70. Changes in the size and number of skin lesions in PB leprosy on treatment and follow-up.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2011 Sep; 82(3):244-52. PubMed ID: 22125932
[TBL] [Abstract][Full Text] [Related]
71. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
72. Ocular hypotension and hypotony in multibacillary leprosy patients; at diagnosis, during and after completion of multidrug therapy.
Daniel E; Rao PS; Ffytche TJ; Courtright P
Indian J Lepr; 2010; 82(4):181-8. PubMed ID: 21434594
[TBL] [Abstract][Full Text] [Related]
73. Relapses during long-term follow up with drug-susceptible M. leprae among multibacillary leprosy patients treated with multidrug therapy regimens; case reports.
Thomas A; Hari L; Nagarajan M; Prabhakar R
Int J Lepr Other Mycobact Dis; 1995 Sep; 63(3):391-4. PubMed ID: 7594922
[TBL] [Abstract][Full Text] [Related]
74. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
Shetty VP; Wakade AV; Ghate SD; Pai VV
Lepr Rev; 2011 Sep; 82(3):235-43. PubMed ID: 22125931
[TBL] [Abstract][Full Text] [Related]
75. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
76. Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
Schalcher TR; Borges RS; Coleman MD; Batista Júnior J; Salgado CG; Vieira JL; Romão PR; Oliveira FR; Monteiro MC
PLoS One; 2014; 9(1):e85712. PubMed ID: 24465659
[TBL] [Abstract][Full Text] [Related]
77. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines.
Balagon MF; Cellona RV; Cruz Ed; Burgos JA; Abalos RM; Walsh GP; Saunderson PR; Walsh DS
Am J Trop Med Hyg; 2009 Nov; 81(5):895-9. PubMed ID: 19861628
[TBL] [Abstract][Full Text] [Related]
78. Problems of leprosy relapse in China.
Li HY
Int J Lepr Other Mycobact Dis; 1993 Mar; 61(1):1-7. PubMed ID: 8326169
[TBL] [Abstract][Full Text] [Related]
79. Clinical and bacteriological progress of highly bacillated BL-LL patients discontinuing treatment after different periods of MDT.
Katoch K; Natarajan M; Bagga A; Katoch VM
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):248-54. PubMed ID: 2071982
[TBL] [Abstract][Full Text] [Related]
80. Effect of Steroid Prophylaxis on Nerve Function Impairment in Multi-bacillary Leprosy Patients on MDT-MB.
Sahay G; Kar HK; Gupta R
Indian J Lepr; 2015; 87(3):133-43. PubMed ID: 26999985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
